Imigran (Sumatriptan)

Sumatriptan works by stimulating serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This leads to vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, thereby reducing migraine pain signals.

The exact dose of Imigran is determined by the prescribing clinician based on individual patient needs and response. The product is supplied as a nasal spray, and the prescriber will specify the number of sprays to be administered for each migraine episode.

Safety of Imigran in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Imigran, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Imigran delivers sumatriptan via the nasal route, offering faster absorption than oral tablets and an alternative for patients who experience nausea or have difficulty swallowing. Compared with other triptans, its efficacy is similar, but the nasal spray may provide quicker onset of relief for some individuals.

Imigran should be stored at room temperature, below 25 °C. Keep the spray bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

Imigran is administered as a nasal spray. The patient should gently blow the nose, insert the nozzle into one nostril, and press the actuator to deliver the prescribed number of sprays. The dose may be repeated after two hours if the migraine persists, but only as directed by a healthcare professional.

Serious risks include coronary vasospasm, myocardial infarction, stroke, severe hypertension, serotonin syndrome (especially when combined with other serotonergic drugs), and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience chest pain, severe headache, visual changes, or signs of an allergic reaction.

Imigran is contraindicated in individuals with known coronary artery disease, uncontrolled hypertension, a history of stroke or transient ischemic attack, hemiplegic or basilar migraine, and those currently taking MAO inhibitors or other triptans. It should also be avoided in patients with known hypersensitivity to sumatriptan or any component of the formulation.